×

What are you searching for?




Healthcare

4 Min read

Phase 1 SCB-313 for Malignant Pleural Effusion Treatment tested by Clover Biopharmaceuticals in Australia

Published On 04 Dec 2019 05:44 AM


SHARE THIS ARTICLE  


According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein, the phase I of SCB-313 trial. Five clinical studies to evaluate SCB-13 and recruit patients from Australia and China.

Director of Pleural ....


Tags : Phase 1 SCB-313, Malignant Pleural Effusion , Treatment , Clover Biopharmaceuticals ,
SHARE THIS ARTICLE  

Leave a comment 

comments (0)